Pancreatic ductal adenocarcinoma (PDAC) remains a refractory disease, with a 5-year overall survival rate of less than 9% and most cases are diagnosed at an advanced stage. The treatment options for PDAC are limited. In addition to traditional surgical resection, radiotherapy and chemotherapy, neoadjuvant treatment methods are currently used. In living organisms, cells must interact and assemble in three-dimensional tissues, and the location of each cell is as important as its intrinsic properties in determining the function of the tissue or the dysfunction of the disease. Spatial omics can make up for the shortcomings of single-cell sequencing technology that cannot obtain cell spatial distribution information. It mainly studies the relative position of cells in tissue samples and is used to reveal the impact of cell spatial distribution on diseases. It mainly detects proteins and their modifications or mRNA. Using the spatial omics analysis platform to deeply analyze the tissue tumor microenvironment is an important reference for in-depth understanding of the biological mechanisms of the occurrence and progression of PDAC and the development of clinically relevant biomarkers for early diagnosis.
Fig. 1. Schematic illustration of spatial multi-omics technology, analysis workflow, and example data. (Hsieh WC, et al., 2022)
Services We Offer
| Services | Description |
|---|---|
| Spatial genomics | Use visualization techniques such as microscopy to study the multicellular structure of tissues and explore the structure and conformation of intracellular components such as DNA, RNA, and chromatin. This information is useful for assessing changes in gene expression and cell function and can be correlated with disease status and progression. |
| Spatial proteomics | The ability to quantify and spatially analyze multiple protein markers in whole tissue sections at single-cell resolution offers the possibility to explore hundreds of protein targets at the subcellular level in a variety of cellular states and conditions. This is critical for understanding the role of microenvironmental heterogeneity in the biological function of organs and for discovering novel protein biomarkers of disease. |
| Spatial epigenomics | Combine microfluidics with high-throughput sequencing technology to detect spatial epigenetic modifications of chromatin in single cells or analyze epigenetic information in tissues of interest in a high-throughput and high-resolution manner. |
| Spatial transcriptomics | Spatial transcriptome markers construct spatial expression maps, which reveal the heterogeneity of different tissue locations and enable comprehensive analysis from gene expression to phenotypic characteristics. It provides a new solution for the study of tissue microenvironment, intercellular signaling pathways and spatial heterogeneity. |
| Spatial metabolomics | Spatial metabolomics is a metabolomics technology based on mass spectrometry imaging. Through in-situ detection of samples, while completing the qualitative and quantitative analysis of metabolites, the spatial dimension information is retained, so that the sample area can be analyzed or the spatial distribution spectrum of specific metabolites can be obtained. It will promote cutting-edge application research such as targeted drug discovery, pathological mechanism analysis, and spatial metabolic network regulation that are closely related to the growth and development of organisms. |
Alfa Cytology is committed to providing customers with one-stop basic research services on pancreatic cancer. If you are interested in our pancreatic cancer spatial omics research service, please contact us for more details.
Reference
- Hsieh WC, et al. Spatial multi-omics analyses of the tumor immune microenvironment. J Biomed Sci. 2022 Nov 14;29(1):96.